Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline

Reuters03-17

Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> publishes corporate presentation on its viral immunotherapy cancer pipeline

Candel outlined its lead program, aglatimagene besadenovec (CAN-2409), describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer (n=745) met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev (CAN-3110), an oncolytic HSV-1 program for recurrent high-grade glioma, and noted Fast Track and Orphan Drug designations for that candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620242084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620242084","market":"fut","top_or_hot":-1,"title":"Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> publishes corporate presentation on its viral immunotherapy cancer pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel outlined its lead program, aglatimagene besadenovec (CAN-2409), describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer (n=745) met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev (CAN-3110), an oncolytic HSV-1 program for recurrent high-grade glioma, and noted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations for that candidate.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> publishes corporate presentation on its viral immunotherapy cancer pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel outlined its lead program, aglatimagene besadenovec (CAN-2409), describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer (n=745) met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev (CAN-3110), an oncolytic HSV-1 program for recurrent high-grade glioma, and noted <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations for that candidate.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TRIN","symbol_name":"Trinity Capital Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL3TXQBm:1","article_id":"2620242084","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620242084","pubTimestamp":1773750369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Candel outlined its lead program, aglatimagene besadenovec , describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer  met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev , an oncolytic HSV-1 program for recurrent high-grade glioma, and noted Fast Track and Orphan Drug designations for that candidate.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TRIN":"Trinity Capital Inc.","BK4135":"资产管理与托管银行","BK4539":"次新股","CADL":"Candel Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Candel Therapeutics发布有关其病毒免疫疗法癌症产品线的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRIN":0.9,"CADL":0.9},"content_text":"Candel Therapeutics publishes corporate presentation on its viral immunotherapy cancer pipeline\n    \n\n        Candel outlined its lead program, aglatimagene besadenovec (CAN-2409), describing it as an off-the-shelf therapy intended to generate an individualized immune response across solid tumors. The company said a randomized phase 3 trial in localized intermediate- to high-risk prostate cancer (n=745) met its primary endpoint of disease-free survival. Candel also cited phase 2a overall survival data for aglatimagene in borderline resectable pancreatic cancer and in therapy-resistant non-small cell lung cancer. It reported cash and cash equivalents of USD 119.7 million as of December 31, 2025 and said it entered into a term loan facility with Trinity Capital of up to USD 130 million. Candel also highlighted linoserpaturev (CAN-3110), an oncolytic HSV-1 program for recurrent high-grade glioma, and noted Fast Track and Orphan Drug designations for that candidate.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620242084","isCrawlerRequest":true}